CENTRE HOSPITALIER DE LUXEMBOURG

Their core work

Centre Hospitalier de Luxembourg (CHL) is Luxembourg's leading public hospital, contributing clinical expertise and patient cohorts to European research on type 1 diabetes and infectious disease preparedness. In H2020, they served as a clinical site for pediatric diabetes technology trials (artificial pancreas systems for young children) and participated in large-scale biomarker discovery and disease mechanism studies. Their role bridges hospital-based patient care with translational research, providing real-world clinical data, biobank samples, and trial infrastructure to multi-country consortia.

What they specialise in

How they've shifted over time

CHL's early H2020 work (2015-2017) was tightly focused on type 1 diabetes — specifically biomarker discovery, biobanking, and testing diabetes technology like closed-loop insulin delivery in children. From 2020 onward, while maintaining their T1D commitment through INNODIA HARVEST, they expanded into pandemic preparedness and infectious disease trials via EU-RESPONSE. This signals a hospital broadening its research portfolio from a single chronic disease specialty toward general clinical trial infrastructure for emerging health threats.

CHL is evolving from a diabetes-only clinical site toward a broader platform trials hub, making them relevant for any consortium needing hospital-based trial infrastructure in Luxembourg.

How they like to work

CHL operates exclusively as a participant — they have never coordinated an H2020 project, which is typical for a hospital contributing clinical sites and patient access rather than driving research agendas. They work in large consortia (74 unique partners across 23 countries), suggesting comfort with complex multi-site clinical trials. Their repeat involvement in INNODIA and its successor INNODIA HARVEST shows loyalty to established networks, making them a reliable long-term partner rather than a one-off contributor.

CHL has collaborated with 74 distinct partners across 23 countries, reflecting the large multi-center clinical trial consortia typical of diabetes and infectious disease research. Their network is thoroughly pan-European with no obvious geographic concentration.

What sets them apart

As Luxembourg's main public hospital, CHL offers something rare: clinical trial access to a small but wealthy EU member state often underrepresented in research consortia. For consortium builders, adding CHL strengthens geographic diversity and provides a well-connected clinical site in a country with high healthcare standards. Their sustained commitment to the INNODIA network (two consecutive projects over 9 years) demonstrates reliability and institutional buy-in for long-term research partnerships.

Highlights from their portfolio

• KidsAP
  Largest grant (EUR 330,275) — tested artificial pancreas in very young children (age 1-7), a particularly challenging and high-impact clinical population.
• INNODIA
  Long-running T1D platform (2015-2023) building a pan-European biobank and clinical trial network, continued into INNODIA HARVEST — showing deep institutional commitment.
• EU-RESPONSE
  Marks CHL's expansion beyond diabetes into pandemic preparedness, joining a European network for emerging infectious disease platform trials.